Activating Transcription Factor 1 is a Prognostic Marker of Colorectal Cancer

  • Huang, Guo-Liang (Sino-American Cancer Research Institute, Guangdong Medical College) ;
  • Guo, Hong-Qiang (The Affiliated Cancer Hospital of Zhengzhou University) ;
  • Yang, Feng (Department of Pharmacy and Life Science, University of South China) ;
  • Liu, Ou-Fei (The Affiliated Cancer Hospital of Zhengzhou University) ;
  • Li, Bin-Bin (Sino-American Cancer Research Institute, Guangdong Medical College) ;
  • Liu, Xing-Yan (Sino-American Cancer Research Institute, Guangdong Medical College) ;
  • Lu, Yan (Sino-American Cancer Research Institute, Guangdong Medical College) ;
  • He, Zhi-Wei (Sino-American Cancer Research Institute, Guangdong Medical College)
  • Published : 2012.03.31


Objective: Identifying cancer-related genes or proteins is critical in preventing and controlling colorectal cancer (CRC). This study was to investigate the clinicopathological and prognostic value of activating transcription factor 1 (ATF1) in CRC. Methods: Protein expression of ATF1 was detected using immunohistochemistry in 66 CRC tissues. Clinicopathological association of ATF1 in CRC was analyzed with chi-square test or Fisher's exact test. The prognostic value of ATF1 in CRC is estimated using the Kaplan-Meier analysis and Cox regression models. Results: The ATF1 protein expression was significantly lower in tumor tissues than corresponding normal tissues (51.5% and 71.1%, respectively, P = 0.038). No correlation was found between ATF1 expression and the investigated clinicopathological parameters, including gender, age, depth of invasion, lymph node status, metastasis, pathological stage, vascular tumoral emboli, peritumoral deposits, chemotherapy and original tumor site (all with P > 0.05). Patients with higher ATF1 expression levels have a significantly higher survival rate than that with lower expression (P = 0.026 for overall survival, P = 0.008 for progress free survival). Multivariate Cox regression model revealed that ATF1 expression and depth of invasion were the predictors of the overall survival (P = 0.008 and P = 0.028) and progress free survival (P = 0.002 and P = 0.005) in CRC. Conclusions: Higher ATF1 expression is a predictor of a favorable outcome for the overall survival and progress free survival in CRC.


  1. Belkhiri A, Dar AA, Zaika A, et al (2008). t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Aktdependent mechanism. Cancer Res, 68, 395-403.
  2. Bhoumik A, Fichtman B, Derossi C, et al (2008). Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc Natl Acad Sci U S A, 105, 1674-9.
  3. Bhoumik A, Jones N, Ronai Z (2004). Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity. Proc Natl Acad Sci U S A, 101, 4222-7.
  4. Bosilevac JM, Olsen RJ, Bridge JA, Hinrichs SH (1999). Tumor cell viability in clear cell sarcoma requires DNA binding activity of the EWS/ATF1 fusion protein. J Biol Chem, 274, 34811-8.
  5. Eferl R, Wagner EF (2003). AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer, 3, 859-68.
  6. Feuerstein ND, Huang S, Hinrichs H, et al (1995). Regulation of cAMP-responsive enhancer binding proteins during cell cycle progression in T lymphocytes stimulated by IL-2. J Immunol, 154, 68-79.
  7. Ghoneim C, Soula-Rothhut M, Blanchevoye C, et al (2007). Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion. J Biol Chem, 282, 15490-7.
  8. Gunderson LL, Jessup JM, Sargent DJ, et al (2010). Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol, 28, 264-71.
  9. Hai T, Hartman MG (2001). The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene, 273, 1-11.
  10. Hsueh YP, Lai MZ (1995). Overexpression of activation transcriptional factor 1 in lymphomas and in activated lymphocytes. J Immunol, 154, 5675-83.
  11. Huang D, Shipman-Appasamy PM, Orten DJ, et al (1994). Promoter activity of the proliferating-cell nuclear antigen gene is associated with inducible CRE-binding proteins in interleukin 2-stimulated T lymphocytes. Mol Cell Biol, 14, 4233-43.
  12. Jean D, Tellez C, Huang S, et al (2000). Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene, 19, 2721- 30.
  13. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  14. Kelly D, Kim SJ, Rizzino A (1998). Transcriptional activation of the type II transforming growth factor-beta receptor gene upon differentiation of embryonal carcinoma cells. J Biol Chem, 273, 21115-24.
  15. Kelly D, Scholtz B, Orten DJ, et al (1995). Regulation of the transforming growth factor-beta 2 gene promoter in embryonal carcinoma cells and their differentiated cells: differential utilization of transcription factors. Mol Reprod Dev, 40, 135-45.
  16. Lopez-Bergam P, Lau E, Ronai Z (2010). Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer, 10, 65-76.
  17. Maekawa T, Sano Y, Shinagawa T, et al (2008). ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors. Oncogene, 27, 1045-54.
  18. Okuyama Y, Sowa Y, Fujita T, et al (1996). ATF site of human RB gene promoter is a responsive element of myogenic differentiation. FEBS Lett, 397, 219-24.
  19. Papassava P, Gorgoulis VG, Papaevangeliou D, et al (2004). Overexpression of activating transcription factor-2 is required for tumor growth and progression in mouse skin tumors. Cancer Res, 64, 8573-84.
  20. Ronai Z, Yang YM, Fuchs SY, et al (1998). ATF2 confers radiation resistance to human melanoma cells. Oncogene, 16, 523-31.
  21. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
  22. Su B, Tang HL, Deng M, et al (2011). Stage-associated dynamic activity profile of transcription factors in nasopharyngeal carcinoma progression based on protein/DNA array analysis. Omics, 15, 49-60.
  23. Zheng D, Cho YY, Lau AT, et al (2008). Cyclin-dependent kinase 3-mediated activating transcription factor 1 phosphorylation enhances cell transformation. Cancer Res, 68, 7650-60.
  24. Zucman J, Delattre O, Desmaze C, et al (1993). EWS and ATF-1 gene fusion induced by t (12;22) translocation in malignant melanoma of soft parts. Nat Genet, 4, 341-5.

Cited by

  1. DEPTOR Expression Negatively Correlates with mTORC1 Activity and Tumor Progression in Colorectal Cancer vol.15, pp.11, 2014,
  2. Lectin from Agrocybe aegerita as a Glycophenotype Probe for Evaluation of Progression and Survival in Colorectal Cancer vol.15, pp.14, 2014,
  3. Down-regulated MYH11 Expression Correlates with Poor Prognosis in Stage II and III Colorectal Cancer vol.15, pp.17, 2014,
  4. Functional annotation of colon cancer risk SNPs vol.5, pp.2041-1723, 2014,
  5. Transcriptome profile of human neuroblastoma cells in the hypomagnetic field vol.57, pp.4, 2014,
  6. GWASeq: targeted re-sequencing follow up to GWAS vol.17, pp.1, 2016,
  7. Transcription factor-microRNA associations and their impact on colorectal cancer survival vol.56, pp.11, 2017,
  8. Colorectal Cancer-Associated Genes Are Associated with Tooth Agenesis and May Have a Role in Tooth Development vol.8, pp.1, 2018,
  9. Comparative expression profile of microRNAs and piRNAs in three ruminant species testes using next-generation sequencing vol.53, pp.4, 2018,